Erenumab for episodic migraine.

Abstract

In this review, the authors provide an overview of erenumab, a monoclonal antibody used for the preventative treatment of episodic migraine by targeting the CGRP pathway. Randomized controlled trials have shown that erenumab is associated with a statistically significant decrease in monthly migraine days in patients with episodic migraine at monthly doses of 70 or 140 mg when given for a period of 9-12 weeks. Post hoc analyses have also shown long-term maintenance of efficacy. Clinical trials have found erenumab at doses of both 70 and 140 mg to have a favorable safety profile. Erenumab faces significant limitations because of its high financial cost. Additional long-term real-world data are needed to understand the role of erenumab in the treatment of migraine.

• Authors: Abhigyan Datta, Sahil Gupta, Shashi Maryala, Vikram Aggarwal, Pooja Chopra, Sameer Jain
• Journal: Pain management (Pain Manag) Vol. 12 Issue 5 Pg. 587-594 (Jul 2022) ISSN: 1758-1877 [Electronic] England
• PMID: 35313740 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• Calcitonin Gene-Related Peptide Receptor Antagonists
• erenumab

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Calcitonin Gene-Related Peptide Receptor Antagonists (pharmacology, therapeutic use)
• Double-Blind Method
• Humans
• Migraine Disorders (drug therapy)
• Treatment Outcome